Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO (CORIMUNO-VIRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04341870
Recruitment Status : Suspended (DSMB recommendation (futility))
First Posted : April 10, 2020
Last Update Posted : May 6, 2020
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
The overall objective of the study is to determine the therapeutic effect and tolerance of Sarilumab in combination with Azithromycin and Hydroxychloroquine, compared to Sarilumab only, patients with moderate, severe pneumonia associated with Coronavirus disease 2019 (COVID-19). Sarilumab is a human IgG1 monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6Rs (sIL-6Rα and mIL-6Rα) and has been shown to inhibit IL-6-mediated signaling through these receptors. The study has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur prior to offering investigational treatments administration to patients enrolled in the CORIMUNO-19 cohort (NCT04324047). Sarilumab+Azithromycin+Hydroxychloroquine, or Sarilumab only will be administered to consenting adult patients hospitalized with COVID-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation. All patients will receive standard of care along with randomized investigational treatments. Outcomes of included patients will be compared between groups as well as with outcomes of patients in the CORIMUNO-19 cohort treated with other immune modulators or standard of care.

Condition or disease Intervention/treatment Phase
COVID19 SARS-CoV-2 Infection Drug: Sarilumab Drug: Azithromycin Drug: Hydroxychloroquine Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Bayesian open labelled randomized clinical trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19: a Multicenter Open-label 1:1 Randomized Controlled Trial
Actual Study Start Date : April 11, 2020
Estimated Primary Completion Date : May 8, 2020
Estimated Study Completion Date : August 2020


Arm Intervention/treatment
Experimental: Sarilumab + Azithromycin + Hydroxychloroquine
Sarilumab combined with Azithromycin and Hydroxychloroquine
Drug: Sarilumab
Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1

Drug: Azithromycin
Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)

Drug: Hydroxychloroquine
Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)

Active Comparator: Sarilumab
Sarilumab only
Drug: Sarilumab
Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1




Primary Outcome Measures :
  1. Need for ventilation (including invasive and non invasive ventilation), intensive care or death [ Time Frame: 14 days ]
    Events considered are: need for ventilation (including invasive and non invasive ventilation), transfer to the Intensive Care Unit, death or new do-not-resuscitate (DNR) decision in the absence ventilation and outside ICU.


Secondary Outcome Measures :
  1. Early improvement: OMS progression scale <= 5 [ Time Frame: 4 days ]
    WHO progression scale: Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2>=150 OR SpO2/FIO2>=200: 7 Mechanical ventilation, (pO2/FIO2<150 OR SpO2/FIO2<200) OR vasopressors (norepinephrine >0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2<150 AND vasopressors (norepinephrine >0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10

  2. OMS progression scale [ Time Frame: 4, 7 and 14 days ]
    WHO progression scale: Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2>=150 OR SpO2/FIO2>=200: 7 Mechanical ventilation, (pO2/FIO2<150 OR SpO2/FIO2<200) OR vasopressors (norepinephrine >0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2<150 AND vasopressors (norepinephrine >0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10

  3. Survival [ Time Frame: 14, 28 and 90 days ]
    Overall survival

  4. ICU-free days alive [ Time Frame: 14, 28 and 90 days ]
    Number of ICU-free days alive

  5. Ventilation-free days alive [ Time Frame: 14 and 28 days ]
    Number of ventilation(invasive or non invasive)-free days alive

  6. Hospital-free days alive [ Time Frame: 14, 28 and 90 days ]
    Number of hospital-free days alive

  7. Oxygen therapy-free days alive [ Time Frame: 14 and 28 days ]
    Number of oxygen therapy-free days alive

  8. Time to negative viral excretion [ Time Frame: 90 days ]
    SARS-CoV-2 viral load measurement by rtPCR

  9. Immunophenotyping and multiplex cytokines [ Time Frame: 8 days ]
    Immunophenotyping and multiplex cytokines (blood sample)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients included in the CORIMUNO-19 cohort (NCT04324047)
  • COVID-19 cases not requiring ICU at admission with moderate or severe pneumopathy according to the WHO Criteria of severity of COVID pneumopathy:

    • Moderate cases: Cases meeting all of the following criteria: [Showing fever and respiratory symptoms with radiological findings of pneumonia] AND [Requiring between 3L/min and 5L/min of oxygen to maintain SpO2>97%] OR
    • Severe cases: Cases meeting any of the following criteria: [Respiratory distress ( ≥ 30 breaths/ min)] OR [Oxygen saturation≤93% at rest in ambient air; or Oxygen saturation ≤97 % with O2 > 5L/min] OR [PaO2/FiO2 ≤ 300mmHg]

Exclusion Criteria:

  1. Patients with exclusion criteria to the CORIMUNO-19 cohort.
  2. Respiratory failure requiring non invasive or mechanical ventilation
  3. Patients requiring intensive care
  4. Do-not-resuscitate order (DNR order)
  5. Known hypersensitivity to sarilumab or to any of their excipients.
  6. Known contra-indication to hydroxychloroquine or chloroquine: including hypersensitivity/allergy, retinopathy, G6PD deficiency and QT prolongation
  7. Known contra-indication to azithromycin: including hypersensitivity/allergy and QT prolongation
  8. Pregnancy or breastfeeding
  9. Current documented bacterial infection.
  10. Patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication:

    • Absolute neutrophil count (ANC) ≤ 1.0 x 109/L
    • Haemoglobin level: no limitation
    • Platelets (PLT) < 50 G /L
    • SGOT or SGPT > 5N

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04341870


Locations
Layout table for location information
France
AP-HP Hôpital Avicenne
Bobigny, France
AP-HP Hôpital Ambroise Paré
Boulogne-Billancourt, France
AP-HP Hôpital Beaujon
Clichy, France
AP-HP Hôpital Pitié Salpétrière
Paris, France
AP-HP Hôpital Saint Antoine
Paris, France
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT04341870    
Other Study ID Numbers: APHP200375-3
First Posted: April 10, 2020    Key Record Dates
Last Update Posted: May 6, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Azithromycin
Hydroxychloroquine
Anti-Bacterial Agents
Anti-Infective Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents